Understanding how proteoglycans affect blood vessel growth in tumors
Proteoglycan regulation of tumor angiogenesis and endothelial cell autophagy
This study is looking at how a protein called endorepellin affects the growth of blood vessels in aggressive breast cancer, with the hope of finding new ways to treat the disease and help patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Thomas Jefferson University NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10977333 on NIH RePORTER |
What this research studies
This research investigates the role of proteoglycans, specifically endorepellin, in regulating blood vessel formation in tumors, particularly in aggressive breast cancer. By examining the interactions between tumor cells and the surrounding environment, the study aims to uncover how these interactions contribute to tumor growth and metastasis. The researchers will explore how endorepellin can inhibit the formation of new blood vessels by targeting specific receptors on endothelial cells, potentially leading to new therapeutic strategies. Patients may benefit from insights gained about tumor biology and potential new treatments that could arise from this work.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with aggressive breast cancer who may benefit from novel anti-angiogenic therapies.
Not a fit: Patients with non-cancerous conditions or those with early-stage breast cancer may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that inhibit tumor growth by blocking blood vessel formation.
How similar studies have performed: Previous research has shown promising results in targeting angiogenesis in cancer, suggesting that this approach may lead to significant advancements in treatment.
Where this research is happening
Philadelphia, United States
- Thomas Jefferson University — Philadelphia, United States (Active)
Researchers
- Principal investigator: Iozzo, Renato V. — Thomas Jefferson University
- Study coordinator: Iozzo, Renato V.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.